日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Extracellular Milieu of Toxoplasma's Lytic Cycle Drives Lab Adaptation, Primarily by Transcriptional Reprogramming

弓形虫裂解周期的细胞外环境主要通过转录重编程驱动其在实验室中的适应性变化

Vincent A Primo Jr # ,Yasaman Rezvani # ,Andrew Farrell ,Connor Q Murphy ,Jingjing Lou ,Amir Vajdi ,Gabor T Marth ,Kourosh Zarringhalam ,Marc-Jan Gubbels

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Talazoparib治疗同源重组修复缺陷型鳞状细胞肺癌患者的II期研究:Lung-MAP子研究S1400G

Owonikoko, Taofeek K; Redman, Mary W; Byers, Lauren A; Hirsch, Fred R; Mack, Philip C; Schwartz, Lawrence H; Bradley, Jeffrey D; Stinchcombe, Thomas E; Leighl, Natasha B; Al Baghdadi, Tareq; Lara, Primo Jr; Miao, Jieling; Kelly, Karen; Ramalingam, Suresh S; Herbst, Roy S; Papadimitrakopoulou, Vassiliki; Gandara, David R

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

17q22拷贝数缺失与转移性去势抵抗性前列腺癌的恩扎卢胺耐药性和不良预后相关

Guan, Xiangnan; Sun, Duanchen; Lu, Eric; Urrutia, Joshua A; Reiter, Robert Evan; Rettig, Matthew; Evans, Christopher P; Lara, Primo Jr; Gleave, Martin; Beer, Tomasz M; Thomas, George V; Huang, Jiaoti; Aggarwal, Rahul R; Quigley, David A; Foye, Adam; Chen, William S; Youngren, Jack; Weinstein, Alana S; Stuart, Joshua M; Feng, Felix Y; Small, Eric J; Xia, Zheng; Alumkal, Joshi J

Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy

多维替尼治疗抗血管内皮生长因子疗法后病情进展患者的II期研究

Semrad, Thomas J; Kim, Edward J; Tanaka, Michael S; Sands, Jacob; Roberts, Chris; Burich, Rebekah A; Li, Yu; Gandara, David R; Lara, Primo Jr; Mack, Philip C

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial

循环肿瘤细胞端粒酶活性作为SWOG 0421研究中总生存期的预后标志物:一项III期转移性去势抵抗性前列腺癌试验

Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M; Tai, Yu-Chong; Xu, Tong; Li, Hongli; Twardowski, Przemyslaw; Veldhuizen, Peter J Van; Agarwal, Neeraj; Carducci, Michael A; Monk, J Paul 3rd; Garzotto, Mark; Mack, Philip C; Lara, Primo Jr; Higano, Celestia S; Hussain, Maha; Vogelzang, Nicholas J; Thompson, Ian M Jr; Cote, Richard J; Quinn, David I

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer

循环肿瘤细胞计数可预测SWOG S0421研究中转移性去势抵抗性前列腺癌患者的总生存期:一项多西他赛联合或不联合阿曲生坦治疗转移性去势抵抗性前列腺癌的III期临床试验

Goldkorn, Amir; Ely, Benjamin; Quinn, David I; Tangen, Catherine M; Fink, Louis M; Xu, Tong; Twardowski, Przemyslaw; Van Veldhuizen, Peter J; Agarwal, Neeraj; Carducci, Michael A; Monk, J Paul 3rd; Datar, Ram H; Garzotto, Mark; Mack, Philip C; Lara, Primo Jr; Higano, Celestia S; Hussain, Maha; Thompson, Ian Murchie Jr; Cote, Richard J; Vogelzang, Nicholas J

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

培美曲塞联合白蛋白紫杉醇治疗晚期实体瘤患者(重点关注非小细胞肺癌)的I/II期临床试验

Ho, Cheryl; Davies, Angela M; Sangha, Randeep S; Lau, Derick; Lara, Primo Jr; Chew, Helen K; Beckett, Laurel; Mack, Philip C; Riess, Jonathan W; Gandara, David R